{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-036358","form_type":"8-K","ticker":"STAA","cik":"0000718937","company_name":"STAAR SURGICAL CO","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.345221+00:00","generated_at":"2026-06-22T15:56:46.896709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"STAAR Surgical Q3 net sales $76M (+30% YoY); ICL units +40%; guides FY22 ~$285M","bullets":["Net sales $76.0M, constant currency $80.0M (+37%); ICL sales $72.0M (+33%), ICL units +40%.","GAAP EPS $0.21, adjusted EPS $0.37 vs. $0.12 and $0.21 in prior year quarter.","Gross margin 79.5% vs 77.6%; operating expenses $46.8M vs $37.5M.","FY22 net sales guided to ~$285M (~$300M constant currency); ICL sales ~$272M (+28% YoY).","Other Products to be phased out by end-2023; FY23 net sales target ~$355M with 30% ICL growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-036358","json":"https://secwatch.observer/filing/0001564590-22-036358.json","markdown":"https://secwatch.observer/filing/0001564590-22-036358.md","text":"https://secwatch.observer/filing/0001564590-22-036358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/718937/000156459022036358/0001564590-22-036358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/718937/000156459022036358/staa-8k_20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T15:56:46.896709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f2e3b158be589f366f8e8b7e886ef9f59637c76","claim":"STAAR SURGICAL CO reported the third quarter ended September 30, 2022 results: revenue $76.0 million, net income $10.3 million or $0.21 per diluted share, EPS $0.21 per diluted share. Guidance reaffirmed.","evidence_excerpt":"STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459022036358/0001564590-22-036358-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$76.0 million"},{"label":"Net income","value":"$10.3 million or $0.21 per diluted share"},{"label":"EPS","value":"$0.21 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}